Scientists create controlled flu infection model to speed up vaccine testing
NCT ID NCT07305207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial aims to safely and reliably cause mild flu symptoms in healthy adults using a lab-made H3N2 influenza virus. By carefully monitoring 32 volunteers, researchers hope to establish a controlled human infection model (CHIM) that can be used in future studies to test new flu vaccines and treatments. Participants will receive either the virus or a placebo via nasal spray and be closely observed for a week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Live recombinant influenza virus (RG-A/Texas/71/2017 H3N2)
- What this could lead to
- If successful, this model could help test future flu vaccines and treatments more efficiently.
- What could go wrong
- This is a very early phase 1 study with only 32 participants. It is designed to cause mild flu symptoms, so some discomfort is expected. The model may not perfectly mimic natural infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a nasal spray flu shot at home beat the needle?
- Flu transmission secrets under the microscope in new human trial
- New study to monitor High-Dose flu shot safety in seniors
- New flu vaccine shows promise in south korean trial
- Super-Sized flu shot shows promise for seniors
- Super-Sized flu shot tested for Seniors' heart and lung protection